Edition:
United States

Allena Pharmaceuticals Inc (ALNA.OQ)

ALNA.OQ on NASDAQ Stock Exchange Global Select Market

13.38USD
22 Jun 2018
Change (% chg)

$0.38 (+2.92%)
Prev Close
$13.00
Open
$13.07
Day's High
$13.73
Day's Low
$12.94
Volume
604,022
Avg. Vol
34,679
52-wk High
$17.55
52-wk Low
$6.15

Chart for

About

Allena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II... (more)

Overall

Beta: --
Market Cap(Mil.): $276.91
Shares Outstanding(Mil.): 20.70
Dividend: --
Yield (%): --

Financials

  ALNA.OQ Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -1.16 -- --
ROI: -- -5.25 13.10
ROE: -- -6.83 15.09

BRIEF-Allena Pharmaceuticals Reports Q1 Loss Per Share $0.38

* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 08 2018

BRIEF-Allena Pharmaceuticals Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $0.48

* ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Mar 27 2018

BRIEF-Allena Pharmaceuticals Initiates First Phase 3 Trial For ALLN-177 In Patients With Enteric Hyperoxaluria

* ALLENA PHARMACEUTICALS INITIATES FIRST PHASE 3 TRIAL FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA

Mar 06 2018

Earnings vs. Estimates